These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31127190)

  • 1. Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer.
    Kretschmer A; Zhang F; Somasekharan SP; Tse C; Leachman L; Gleave A; Li B; Asmaro I; Huang T; Kotula L; Sorensen PH; Gleave ME
    Sci Rep; 2019 May; 9(1):7826. PubMed ID: 31127190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
    Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
    Yang L; Xie S; Jamaluddin MS; Altuwaijri S; Ni J; Kim E; Chen YT; Hu YC; Wang L; Chuang KH; Wu CT; Chang C
    J Biol Chem; 2005 Sep; 280(39):33558-65. PubMed ID: 16061480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophages enhance 3D invasion in a breast cancer cell line by induction of tumor cell tunneling nanotubes.
    Carter KP; Hanna S; Genna A; Lewis D; Segall JE; Cox D
    Cancer Rep (Hoboken); 2019 Dec; 2(6):e1213. PubMed ID: 32467880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
    Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
    Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
    Liu Z; Zhu G; Getzenberg RH; Veltri RW
    J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tunneling-nanotube development in astrocytes depends on p53 activation.
    Wang Y; Cui J; Sun X; Zhang Y
    Cell Death Differ; 2011 Apr; 18(4):732-42. PubMed ID: 21113142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential identity of Filopodia and Tunneling Nanotubes revealed by the opposite functions of actin regulatory complexes.
    Delage E; Cervantes DC; Pénard E; Schmitt C; Syan S; Disanza A; Scita G; Zurzolo C
    Sci Rep; 2016 Dec; 6():39632. PubMed ID: 28008977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
    Lee TJ; Sartor O; Luftig RB; Koochekpour S
    Mol Cancer; 2004 Nov; 3():31. PubMed ID: 15548330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.
    Lin HK; Hu YC; Yang L; Altuwaijri S; Chen YT; Kang HY; Chang C
    J Biol Chem; 2003 Dec; 278(51):50902-7. PubMed ID: 14555644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
    Rybalkina EIu; Stromskaia TP; Ovchinnikov LP; Stavrovskaia AA
    Vopr Onkol; 2013; 59(5):623-8. PubMed ID: 24260892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.